Mylan Launches New Strength of Generic Doryx
Mylan announced the launch of Doxycycline Hyclate Delayed-Release Tablets 50mg, the generic version of Mayne's Doryx. The final approval from the Food and Drug Administration (FDA) for the supplemental Abbreviated New Drug Application (sANDA) grants 180 days of marketing exclusivity.
This marks the first generic version in this dosage strength; Mylan also recently announced the launch of Doxycycline Hyclate Delayed-Release 200mg.
Doryx is a tetracycline antibiotic indicated as adjunctive therapy for severe acne. It works by inhibiting bacterial protein synthesis by binding to the 30S ribosomal subunit. Doxycycline has bacteriostatic activity against a broad range of Gram-positive and Gram- negative bacteria.
For more information call (800) RX-MYLAN or visit Mylan.com.